Immuneering Corporation

Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

Content by Immuneering Corporation

Graphic of a human’s internal organs, with the pancreas highlighted in yellow

A Slow and Steady Approach to Pancreatic Cancer Therapy

The ScientistandImmuneering Corporation | | 5 min read

Page 1 of 1 - 1 Total Items

Image of a man in a laboratory looking frustrated with his failed experiment.

February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.

Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.

Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Collaboration will bring next generation orchestration and modular automation to scientists worldwide

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.